PhoreMost Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 32

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 12

PhoreMost General Information

Description

Operator of a drug target identification and drug discovery company, intended to identify new targets or drugs for future therapy. The company's platform provides cryptic druggable sites in the human genome and directly links them to useful therapeutic functions in a live-cell context, and then uses these functionally validated protein fragments to inform the design of small molecule drugs with the same shape, enabling medical practitioners to continue the pipeline of highly validated first-in-class drug discovery programs for out-licensing to pharma.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Moneta Building, B280
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom
+44 01223
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Moneta Building, B280
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom
+44 01223

PhoreMost Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PhoreMost Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private 01-Feb-2026 Completed Pre-Clinical Trials
8. Later Stage VC (Series B) 10-Sep-2024 Completed Pre-Clinical Trials
7. Later Stage VC 01-Jan-2021 Completed Pre-Clinical Trials
6. Early Stage VC (Series A) 30-Apr-2018 Completed Pre-Clinical Trials
5. Grant 27-Apr-2018 Completed Pre-Clinical Trials
4. Early Stage VC 03-Mar-2017 Completed Pre-Clinical Trials
3. Grant 13-May-2015 Completed Pre-Clinical Trials
2. Seed Round 11-Mar-2015 $6.12M $6.12M Completed Pre-Clinical Trials
1. University Spin-Out 01-Apr-2014 Completed Startup
To view PhoreMost’s complete valuation and funding history, request access »

PhoreMost Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A1 Ordinary
A Ordinary
A Ordinary
A Ordinary 46,700 $0.001307 $55.95 $55.95 1x $55.95 7.83%
A Ordinary 65,311 $0.001307 $50.81 $50.81 1x $50.81 10.96%
To view PhoreMost’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

PhoreMost Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a drug target identification and drug discovery company, intended to identify new targets or drugs for futur
Drug Discovery
Cambridge, United Kingdom
32 As of 2026

Leiden, Netherlands
 

Philadelphia, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PhoreMost Competitors (70)

One of PhoreMost’s 70 competitors is Ncardia, a Venture Capital-Backed company based in Leiden, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ncardia Venture Capital-Backed Leiden, Netherlands
Integral Molecular Private Debt Financed Philadelphia, PA
Virometix Venture Capital-Backed Schlieren, Switzerland
Circle Pharma Venture Capital-Backed South San Francisco, CA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 70 competitors. Get the full list »

PhoreMost Patents

PhoreMost Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202510328-D0 Small molecule and applications of the same Pending 27-Jun-2025
GB-202407128-D0 Methods of protein engineering and functional screening Inactive 20-May-2024
GB-202319002-D0 Methods of protein engineering and functional screening Inactive 13-Dec-2023
EP-4784781-A1 Methods of protein engineering and functional screening Pending 28-Sep-2023
GB-202314894-D0 Methods of protein engineering and functional screening Inactive 28-Sep-2023
To view PhoreMost’s complete patent history, request access »

PhoreMost Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PhoreMost Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
5Y Capital Venture Capital Minority
Astellas Venture Management Corporate Venture Capital Minority
Meltwind Advisory Venture Capital Minority
Trend Investment Group Venture Capital Minority
XtalPi Technology Corporation Minority
You’re viewing 5 of 12 investors. Get the full list »

PhoreMost FAQs

  • When was PhoreMost founded?

    PhoreMost was founded in 2014.

  • Where is PhoreMost headquartered?

    PhoreMost is headquartered in Cambridge, United Kingdom.

  • What is the size of PhoreMost?

    PhoreMost has 32 total employees.

  • What industry is PhoreMost in?

    PhoreMost’s primary industry is Drug Discovery.

  • Is PhoreMost a private or public company?

    PhoreMost is a Private company.

  • What is PhoreMost’s current revenue?

    The current revenue for PhoreMost is .

  • How much funding has PhoreMost raised over time?

    PhoreMost has raised $83M.

  • Who are PhoreMost’s investors?

    5Y Capital, Astellas Venture Management, Meltwind Advisory, Trend Investment Group, and XtalPi Technology are 5 of 12 investors who have invested in PhoreMost.

  • Who are PhoreMost’s competitors?

    Ncardia, Integral Molecular, Virometix, Circle Pharma, and CytomX Therapeutics are some of the 70 competitors of PhoreMost.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process